REAL-TIME GLOBAL RESEARCH
SMID Cap in Focus – Our Biotech 2Q Focus
Research evidence excerpt
SMID Cap in Focus – Our Biotech 2Q Focus
search analyst's household.
Morgan Stanley & Co. LLC makes a market in the securities of 4D Molecular Therapeutics Inc, ABSCI CORP, Acadia Pharmaceuticals Inc, Alector Inc, Alumis Inc., Arcus Biosciences Inc., Arcutis
Biotherapeutics, Inc., Arrowhead Pharmaceuticals Inc, Arvinas Inc, Atea Pharmaceuticals Inc, BeOne Medicines, Bicara Therapeutics, Bicycle Therapeutics Plc, BioAge Labs Inc, Biogen Inc, Biohaven
Ltd, Celldex Therapeutics Inc, CG Oncology, Crinetics Pharmaceuticals, Cullinan Therapeutics, Denali Therapeutics Inc, Disc Medicine Inc, Dyne Therapeutics Inc, Generate Biomedicines Inc,
Immunocore Holdings Ltd, Incyte Corp, Intellia Therapeutics Inc, Ionis Pharmaceuticals Inc, Kalaris Therapeutics, Kymera Therapeutics Inc, Kyverna Therapeutics, MapLight Therapeutics, Mirum
Pharmaceuticals, Nurix Therapeutics Inc., Organon & Co., Pharvaris N.V., ProKidney Corp, PTC Therapeutics, Regeneron Pharmaceuticals Inc., Regenxbio Inc, Rhythm Pharmaceuticals Inc, Rocket
Pharmaceuticals Inc, Sana Biotechnology, Inc, Schrodinger Inc., Silence Therapeutics Plc, Trevi Therapeutics Inc, Ultragenyx Pharmaceutical Inc, United Therapeutics Corp, Vir Biotechnology Inc,
Zenas Biopharma Inc.
The equity research analysts or strategists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality
of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues. Equity Research analysts' or strategists' compensation is not
linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.
The English excerpt is extracted automatically from the cited source page and may contain layout or recognition errors. It is never batch translated.
Open report viewer